We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

Do Loxapine Plus Cyproheptadine Make an Atypical Antipsychotic? PET Analysis of Their Dopamine D2 and Serotonin2 Receptor Occupancy

Herbert Meltzer, MD
Arch Gen Psychiatry. 1998;55(7):667-668. doi:.
Text Size: A A A
Published online


In reply

The interesting letter by Kapur et al raises a number of issues that I have been intimately involved with for nearly a decade, issues on which our views sometimes differ significantly. I have proposed that atypical antipsychotic drugs such as clozapine, risperidone, and olanzapine are appropriately defined as antipsychotics with low extrapyramidal symptoms (low EPS) at average clinical doses, and that attempts to expand this definition to include additional actions that only some of these drugs have, such as a greater ability to improve negative symptoms, are ill advised.1 In fact, the historic definition of an atypical antipsychotic agent included low EPS at clinically effective antipsychotic doses. There is not yet evidence for any other single property shared by all of the new atypical drugs, including the ability to improve negative symptoms to a greater extent than typical neuroleptic drugs. Other differences have emerged with regard to cognitive function and prolactin secretion as well as efficacy in patients who are resistant to treatment.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.